BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kerckhove N, Scanzi J, Pereira B, Ardid D, Dapoigny M. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial. BMJ Open 2017;7:e015380. [PMID: 28720615 DOI: 10.1136/bmjopen-2016-015380] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Kerckhove N, Boudieu L, Ourties G, Bourdier J, Daulhac L, Eschalier A, Mallet C. Ethosuximide improves chronic pain-induced anxiety- and depression-like behaviors. Eur Neuropsychopharmacol 2019;29:1419-32. [PMID: 31767519 DOI: 10.1016/j.euroneuro.2019.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hoppanova L, Lacinova L. Voltage-dependent CaV3.2 and CaV2.2 channels in nociceptive pathways. Pflugers Arch 2022. [PMID: 35043234 DOI: 10.1007/s00424-022-02666-y] [Reference Citation Analysis]
3 El-haggar SM, Hegazy SK, Abd-elsalam SM, Elkaeed EB, Al-karmalawy AA, Bahaa MM. A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial. JIR 2022;Volume 15:1159-72. [DOI: 10.2147/jir.s346608] [Reference Citation Analysis]
4 El-Haggar SM, Hegazy SK, M Abd-Elsalam S, Bahaa MM. Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to Irritable Bowel Syndrome. J Clin Pharm Ther 2021. [PMID: 34726293 DOI: 10.1111/jcpt.13556] [Reference Citation Analysis]
5 El-Haggar SM, Hegazy SK, Abd-Elsalam SM, Bahaa MM. Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. Biomed Pharmacother 2022;145:112399. [PMID: 34775240 DOI: 10.1016/j.biopha.2021.112399] [Reference Citation Analysis]
6 Zheng H, Jin S, Shen YL, Peng WY, Ye K, Tang TC, Zhao J, Chen M, Li ZG. Chinese Herbal Medicine for Irritable Bowel Syndrome: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol 2021;12:694741. [PMID: 34385918 DOI: 10.3389/fphar.2021.694741] [Reference Citation Analysis]
7 Picard E, Carvalho FA, Agosti F, Bourinet E, Ardid D, Eschalier A, Daulhac L, Mallet C. Inhibition of Cav 3.2 calcium channels: A new target for colonic hypersensitivity associated with low-grade inflammation. Br J Pharmacol 2019;176:950-63. [PMID: 30714145 DOI: 10.1111/bph.14608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
8 Elwing JE, Atassi H, Rogers BD, Sayuk GS. Emerging therapies in the management of Irritable Bowel Syndrome (IBS). Expert Opin Emerg Drugs 2022. [PMID: 35266839 DOI: 10.1080/14728214.2022.2052043] [Reference Citation Analysis]